11 September 2006 The photosensitizer talaporfinum caused microvascular embolization for photodynamic therapy
Author Affiliations +
Proceedings Volume 5967, 2004 Shanghai International Conference on Laser Medicine and Surgery; 59670V (2006) https://doi.org/10.1117/12.639220
Event: 2004 Shanghai international Conference on Laser Medicine and Surgery, 2004, Shanghai, China
Abstract
Photodynamic therapy (PDT) has been evolving rapidly in the recent years. A second-generation Photosensitizer mono-1-aspartyl chlorine 6 (Talaporfin / Npe6 / ME2906, Japan Meiji Seika, Ltd.) has been sanctified for the lung cancer clinical PDT by the Japan Ministry of Health, Labor and Welfare. In this paper, Talaporfin was injected to the implant cancer of a mouse a Talaporfin dose of 5mg/kg through intravenous. After 6 hours, the fluorescence images of the mouse were observed with a microscope and a 664 nm diode laser. Effects of therapy were clarified using the different irradiation energies of the laser (50, 100, 200 J/cm2). Both in plasma and in cancer, the concentrations of Talaporfin were analyzed using High Performance Liquid Chromatography (HPLC). Authors find that the higher concentrations of Talaporfin in plasma, the better PDD effect. It is experimentally verified that local microvascular embolisms in the cancer are formed for photodynamic therapy after the Talaporfin injection and the laser irradiation.
© (2006) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Liming Li, Katsuo Aizawa, "The photosensitizer talaporfinum caused microvascular embolization for photodynamic therapy", Proc. SPIE 5967, 2004 Shanghai International Conference on Laser Medicine and Surgery, 59670V (11 September 2006); doi: 10.1117/12.639220; https://doi.org/10.1117/12.639220
PROCEEDINGS
4 PAGES


SHARE
Back to Top